Poor
Not Aligned
Patient Risk:
Low
Summary
Only one claim (“Tecentriq is a cancer treatment”) is supported by the provided FDA label sections. All other claims concern UK approvals, patent timelines, and EU/UK biosimilar policy/economic expectations, which are absent from the supplied FDA label content.
Category Scores
Accurate Statements
Tecentriq (atezolizumab) is a cancer treatment.
Supported by indications in provided label sections (1.1 Non-Small Cell Lung Cancer; 1.4 Melanoma; 1.6 Muscle Invasive Bladder Cancer).
Unsupported Statements
Tecentriq was approved in the UK for treating non-small cell lung cancer.
Absent from the supplied FDA label sections.
Tecentriq was approved in the UK for treating triple-negative breast cancer.
Absent from the supplied FDA label sections.
The patent for Tecentriq is expected to expire in the UK in 2027.
Patent/market exclusivity timeline not provided in the supplied FDA label sections.
Under the EU Biosimilars Policy, biosimilars can be approved for marketing in the EU up to 8 years before the reference medicine's patent expires.
EU biosimilar policy content not present in the supplied FDA label sections.
Biosimilar manufacturers must demonstrate that their product has comparable efficacy and safety to the reference medicine.
Biosimilar regulatory requirements not present in the supplied FDA label sections.
Biosimilar manufacturers must demonstrate a high degree of similarity in quality to the reference medicine.
Biosimilar regulatory requirements not present in the supplied FDA label sections.
The UK's MHRA has stated that it will follow the EU's guidelines on biosimilars.
MHRA statements not present in the supplied FDA label sections.
In the UK, biosimilar applications will be assessed on a case-by-case basis.
UK regulatory process not present in the supplied FDA label sections.
Once the patent for Tecentriq expires in the UK, other companies can begin manufacturing and selling biosimilars.
Manufacturing/sales entry tied to patent expiry not present in the supplied FDA label sections.
When biosimilars enter the market, they are likely to be priced at a lower cost than the original product.
Pricing expectations are not present in the supplied FDA label sections.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are mainly regulatory/timeline/policy/economic statements rather than dosage, contraindications, boxed warnings, or safety/monitoring instructions from the provided FDA label; no direct label-based safety content was asserted or omitted for clinical use within this claim set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most claims are regulatory/patent/biosimilar-policy and market/price predictions that are absent from the supplied FDA label sections.
Suggested Improvement
Limit statements to content actually present in the provided FDA label (e.g., FDA-supported indications/dosing/safety sections). Remove or clearly qualify any UK/EU biosimilar policy, patent timeline, and pricing assertions that are not found in the label excerpts provided.